The Uterine Leiomyoma (Uterine Fibroids) drugs in development market research report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Uterine Leiomyoma (Uterine Fibroids). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued products.

GlobalData tracks 14 drugs in development for Uterine Leiomyoma (Uterine Fibroids) by 15 companies/universities/institutes. The top development phase for Uterine Leiomyoma (Uterine Fibroids) is preclinical with five drugs in that stage. The Uterine Leiomyoma (Uterine Fibroids) pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Uterine Leiomyoma (Uterine Fibroids) pipeline products market are: Foresee Pharmaceuticals, Kissei Pharmaceutical and Eurofarma Laboratorios.

The key targets in the Uterine Leiomyoma (Uterine Fibroids) pipeline products market include Gonadotropin Releasing Hormone Receptor (GNRHR), Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR), and Estrogen Receptor (ESR).

The key mechanisms of action in the Uterine Leiomyoma (Uterine Fibroids) pipeline product include Gonadotropin Releasing Hormone Receptor (GNRHR) Antagonist with four drugs in Filing rejected/Withdrawn. The Uterine Leiomyoma (Uterine Fibroids) pipeline products include three routes of administration with the top ROA being Oral and three key molecule types in the Uterine Leiomyoma (Uterine Fibroids) pipeline products market including Small Molecule, and Synthetic Peptide.

Uterine Leiomyoma (Uterine Fibroids) overview

Uterine leiomyoma, also known as uterine fibroids, are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods (seven days or more of menstrual bleeding), pelvic pressure or pain, frequent urination, difficulty emptying the bladder, constipation, and backache or leg pain.

For a complete picture of Uterine Leiomyoma (Uterine Fibroids)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.